Phase 1 Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have multiple myeloma that has either come back after treatment (relapsed) or stopped responding to treatment (refractory), as confirmed by their doctor using standard international guidelines.
- People whose myeloma has measurable signs of the disease in their blood or urine, detected within 28 days before enrolling — this includes specific protein levels in the blood or urine, or abnormal levels of certain proteins called free light chains.
- People who have already been through three or more previous rounds of treatment, including at least one treatment from each of these three types: a proteasome inhibitor, an immunomodulatory drug (IMiD), and an anti-CD38 therapy — and for whom other available treatments are no longer suitable or accessible.
Who may not be able to join:
- People who have a known history of multiple myeloma that has spread to the brain or spinal cord (the central nervous system).
- People who have a history of certain lung conditions, including idiopathic pulmonary fibrosis, organising pneumonia, or inflammation of the lungs caused by medication or of unknown origin.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: ABBVIE INC., AbbVie
Phone: 844-663-3742
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Participants With Adverse Events (AE); Number of Participants With Clinically Significant Changes From Baseline in Clinical Laboratory Parameters; Number of Participants With Clinically Significant Changes From Baseline in Vital Sign Parameters; Number of Participants With Clinically Significant Changes From Baseline in Electrocardiograms (ECG)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.